guest ::
| Home > Publications database > Low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs and epithelial ovarian cancer survival: a registry-based cohort study in Norway. |
| Home > Publications database > Low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs and epithelial ovarian cancer survival: a registry-based cohort study in Norway. |
| Journal Article | DKFZ-2025-00905 |
; ; ; ;
2025
BioMed Central
London
This record in other databases: 
Please use a persistent id in citations: doi:10.1186/s12885-025-14168-y
Abstract: Aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NA-NSAID) have been associated with improved survival in individuals with epithelial ovarian cancer (EOC); however, findings to date are inconsistent.We conducted a registry-based cohort study evaluating survival following an incident invasive EOC diagnosis including individuals diagnosed between 2004-2018 (n = 4325; n = 2206 deaths; n = 1973 EOC deaths). Evaluated exposures were low-dose aspirin and NA-NSAIDs. Two primary post-diagnosis exposure windows were evaluated: fixed post-diagnostic baseline exposure ≤ 305 days after diagnosis (use, non-use) and updated 'time-varying' exposure (never, past, current use; cumulative defined daily dose (DDD)). Pre-diagnostic exposure (use, non-use) was further evaluated. Multivariable Cox-proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals [95% CIs]. The primary outcome was cause-specific survival. Restricted mean survival time (RMST) in exposure groups was estimated at 5 years following start of follow-up.Baseline post-diagnosis aspirin use was not associated with survival following an EOC diagnosis (e.g., use vs. no use: aspirin, HR = 1.02 [95% CI = 0.84-1.24]). Inverse associations were observed between current aspirin use post-diagnosis and survival in the time-varying exposure models (HR 0.68 [0.57-0.81]), and with higher post-diagnosis cumulative DDD of aspirin. Findings for NA-NSAIDs were less consistent. No associations were observed for pre-diagnostic use. Results for overall survival were similar to those for cause-specific survival. Compared to never use, post-diagnosis low-dose aspirin use was associated with a longer RMST (e.g., ever vs. never use, difference in RMST = 2.67 months).This study provides further evidence of a potential beneficial effect of post-diagnosis low-dose aspirin use for ovarian cancer survival.
Keyword(s): Humans (MeSH) ; Female (MeSH) ; Aspirin: administration & dosage (MeSH) ; Aspirin: therapeutic use (MeSH) ; Anti-Inflammatory Agents, Non-Steroidal: administration & dosage (MeSH) ; Anti-Inflammatory Agents, Non-Steroidal: therapeutic use (MeSH) ; Carcinoma, Ovarian Epithelial: mortality (MeSH) ; Carcinoma, Ovarian Epithelial: drug therapy (MeSH) ; Registries: statistics & numerical data (MeSH) ; Norway: epidemiology (MeSH) ; Middle Aged (MeSH) ; Aged (MeSH) ; Ovarian Neoplasms: mortality (MeSH) ; Ovarian Neoplasms: drug therapy (MeSH) ; Cohort Studies (MeSH) ; Adult (MeSH) ; Proportional Hazards Models (MeSH) ; Aspirin ; Non-aspirin NSAIDs ; Ovarian cancer ; Survival ; Aspirin ; Anti-Inflammatory Agents, Non-Steroidal
; 
; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
